Fenofibric acid (Trilipix)

For high-risk patients with mixed dyslipidemia indicated as an adjunct t diet in combination with a statin to reduce triglycerides and increase HDL-cholesterol.

First and only fibrate approved by the FDA for combination with statins.

Maximum dose is 135 mg once daily.

Initiate 45 mg once daily dosing in the presence of mild to moderate renal impairment.

Use avoided with marked renal impairment.

In combination with statin therapy increases risk of myositis or myopathy and have been associated with rhabdomyolysis.

Reversible elevations of creatinine reported.

May lead to cholelithiasis.

May potentiate the effects of warfarin.

Most common side effects with statin therapy include dyspepsia, nausea, nasopharyngitis, URI, arthralgias, back pain, extremity pain, dizziness, and headache.

Leave a Reply

Your email address will not be published. Required fields are marked *